{"body":"<div class=\"new_recommend \">&#13;\n<h5>Good practice statement (2016)<\/h5>&#13;\n&#13;\n<p><strong>ART should be initiated urgently among all pregnant and breastfeeding women living with HIV, even if they are identified late in pregnancy or postpartum, because the most effective way to prevent HIV vertical transmission is to reduce maternal viral load.\u1d43<\/strong><\/p>&#13;\n&#13;\n<div class=\"footer\">&#13;\n<div class=\"footer-links\">\u1d43 Whenever possible, all efforts should be made to identify HIV-infected pregnant women early enough to avoid the need for enhanced prophylaxis.<\/div>&#13;\n&#13;\n<div class=\"footer-links\">\u00a0<\/div>&#13;\n&#13;\n<div class=\"footer-links\">&#13;\n<div class=\"footer\">Source: <em>Consolidated guidelines on the use<\/em> <em>of<\/em><em> antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach - second edition (13).<\/em><\/div>&#13;\n<\/div>&#13;\n<\/div>&#13;\n<\/div>&#13;\n&#13;\n<div class=\"new_recommend \">&#13;\n<h5>Recommendations (2016)<\/h5>&#13;\n&#13;\n<p><strong>\u2022<\/strong> <strong>Infants born to mothers with HIV who are at high risk of acquiring HIV\u1d43 should receive dual prophylaxis with daily AZT and NVP for the first six weeks of life, whether they are breastfed or formula fed<\/strong> <em>(strong recommendation, moderate-certainty evidence).<\/em><\/p>&#13;\n&#13;\n<p><strong>\u2022<\/strong> <strong>Breastfed infants who are at high risk of acquiring HIV\u1d43, including those first identified as exposed to HIV during the postpartum period, should continue infant prophylaxis for an additional six weeks (total of 12 weeks of infant prophylaxis) using either AZT and NVP or NVP alone<\/strong> <em>(conditional recommendation, low-certainty evidence).<\/em><\/p>&#13;\n&#13;\n<p><strong>\u2022<\/strong> <strong>Infants of mothers who are receiving ART and are breastfeeding should receive six weeks of infant prophylaxis with daily NVP. If infants are receiving replacement feeding, they should be given four to six weeks of infant prophylaxis with daily NVP (or twice-daily AZT)<\/strong> <em>(strong recommendation, moderate-certainty evidence for breastfeeding infants; strong recommendation, low-certainty evidence for infants receiving only replacement feeding).<\/em><\/p>&#13;\n&#13;\n<div class=\"footer\">&#13;\n<div class=\"footer-links\">&#13;\n<p>\u1d43 High-risk infants are defined as those:<\/p>&#13;\n&#13;\n<div class=\"footer\">&#13;\n<div class=\"footer-links\">- born to women with established HIV infection who have received less than four weeks of ART at the time of delivery; or<\/div>&#13;\n&#13;\n<div class=\"footer-links\">\u00a0<\/div>&#13;\n&#13;\n<div class=\"footer-links\">&#13;\n<div class=\"footer\">&#13;\n<div class=\"footer-links\">- born to women with established HIV infection with viral load &gt;1000 copies\/mL in the four weeks before delivery, if viral load is available; or<\/div>&#13;\n&#13;\n<div class=\"footer-links\">\u00a0<\/div>&#13;\n&#13;\n<div class=\"footer-links\">&#13;\n<div class=\"footer\">&#13;\n<p>- born to women with incident HIV infection during pregnancy or breastfeeding; or<\/p>&#13;\n&#13;\n<div class=\"footer\">&#13;\n<div class=\"footer-links\">- born to women identified for the first time during the postpartum period, with or without a negative HIV test prenatally.<\/div>&#13;\n&#13;\n<div class=\"footer-links\">&#13;\n<div class=\"footer\">&#13;\n<div class=\"footer-links\">\u00a0<\/div>&#13;\n<em>Source: Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach \u2013 second edition (13).<\/em><\/div>&#13;\n<\/div>&#13;\n<\/div>&#13;\n<\/div>&#13;\n<\/div>&#13;\n<\/div>&#13;\n<\/div>&#13;\n<\/div>&#13;\n<\/div>&#13;\n<\/div>&#13;\n<\/div>&#13;\n&#13;\n<h5>Background<\/h5>&#13;\n&#13;\n<p>Despite decades of progress in decreasing rates of vertical (mother-to-child) transmission, children continue to acquire HIV. Even with expanded treatment coverage for women with HIV, perinatal transmission continues to occur among infants born to women with HIV diagnosed in pregnancy or at delivery. Infants are also at risk of acquiring HIV during breastfeeding from a woman living with HIV. Roughly half of all newly infected children acquire HIV during breastfeeding. Although countries continue to make progress, challenges remain in retaining women living with HIV in health-care services and on effective ART throughout pregnancy and the breastfeeding period as well as detecting women who acquire during pregnancy and breastfeeding and preventing this from happening. Addressing these gaps requires continuing to emphasize promoting universal testing and treatment in the antenatal period and retesting HIV-negative women during pregnancy, at delivery and during breastfeeding to identify incident HIV, especially in settings with a high burden of HIV infection. In addition, it is important to consider the need for enhanced infant prophylaxis for the infants born to mothers that have not received early, effective ART.<\/p>&#13;\n&#13;\n<p>The 2016 WHO consolidated HIV guidelines recommend a dual regimen of AZT and NVP for infants deemed to be at high risk of vertical transmission, which can be extended for up to 12 weeks for breastfeeding infants <em>(13).<\/em> A high-risk infant is defined as an infant whose mother was first identified as HIV-infected at delivery or in the postpartum, infected during pregnancy or breastfeeding, started ART late in pregnancy or did not achieve viral suppression by the time of delivery (Fig. 3.1). All high-risk infants should receive dual drug prophylaxis (AZT plus NVP) for the first six weeks. For breastfeeding infants, this should be followed by either an extra six weeks of AZT plus NVP or an extra six weeks of NVP alone.<\/p>&#13;\n&#13;\n<p>WHO guidelines on infant feeding <em>(123)<\/em> in relation to HIV reaffirm the position of WHO that the best way to prevent vertical transmission in the postpartum period and optimize infant survival is to ensure that mothers living with HIV are receiving ART, have suppressed viral loads and are able to breastfeed their infants for up to two years, with the infant being exclusively breastfed in the initial six months. If a mother receiving ART has suppressed viral loads, the risk of breast-milk transmission is very low and infant prophylaxis confers minimal additional benefit beyond 4-6 weeks of life.<\/p>&#13;\n&#13;\n<p>Since the release of the 2016 WHO consolidated HIV guidelines, countries have adopted enhanced postnatal prophylaxis using a variety of different approaches to adapt to the country context and challenges. In about one third of AIDS Free priority countries (Burundi, Eswatini, Ethiopia, Ghana, Kenya, Mozambique and Zambia), enhanced postnatal prophylaxis has been adopted for all breastfeeding HIV-exposed infants, and the remaining countries have adopted enhanced postnatal prophylaxis for high-risk infants identified primarily based on maternal ART duration and, when available, maternal viral load close to delivery. Most countries opted for at least 12 weeks of prophylaxis, usually AZT + NVP for the first six weeks followed by NVP alone. Five countries (Eswatini, Kenya, Namibia, South Africa and Zambia) link the duration of enhanced postnatal prophylaxis to the maternal viral load and extend enhanced postnatal prophylaxis over the entire breastfeeding period when viral suppression is not achieved. Finally, in three countries (Botswana, United Republic of Tanzania and Zambia), administration of three drugs in a fixed-dose dispersible tablet formulation based on AZT + 3TC + NVP has been adopted to address the challenges of procuring individual liquid formulations.<\/p>&#13;\n&#13;\n<h5>Evidence for the recommendation<\/h5>&#13;\n&#13;\n<p>This recommendation is based on evidence from randomized clinical trials <em>(124)<\/em> and considers the risk-benefit ratio of enhanced postnatal prophylaxis: potential for increased drug toxicity versus additional protection from HIV transmission <em>(13).<\/em> The systematic review <em>(124)<\/em> focused on studies that report on outcomes following the use of combined and\/or prolonged infant prophylaxis regimens compared with the current standard of care. Although some of the studies reviewed were conducted in settings in which formula feeding is the norm, the findings can still be applied to breastfeeding populations since intrapartum HIV transmission is an important driver of vertical HIV transmission in both settings. Four studies met the criteria for inclusion, of which two were randomized trials <em>(125,126)<\/em> and two were observational studies <em>(127,128).<\/em><\/p>&#13;\n&#13;\n<ul><li>The intrapartum transmission rate was found to be significantly lower with the two-drug and the three-drug regimens versus AZT alone (126). Serious adverse events possibly or probably related to study drugs were more frequent with the three-drug regimen than with AZT-alone or the two-drug group.<\/li>&#13;\n\t<li>In a breastfed population, infants who received six months of NVP experienced a 54% lower transmission rate at six months compared with those who received only six weeks of NVP <em>(126).<\/em> However, among the infants born to mothers receiving ART at the time of randomization, the postnatal transmission rate was extremely low and did not differ between those who received longer duration NVP prophylaxis versus placebo.<\/li>&#13;\n\t<li>In a large European cohort of \"high-risk\" mother-infant pairs, no difference was reported in serious adverse events between infants who received one, two or three drugs. When neutropaenia was compared between the two-drug and three-drug arms, there was a trend towards more events in the three-drug arm, but this was not statistically significant <em>(127).<\/em><\/li>&#13;\n\t<li>A single-arm study in non-breastfeeding infants of mothers who received less than eight weeks of antepartum ART in Thailand gave infant prophylaxis with AZT + 3TC + NVP for two weeks, followed by AZT + 3TC for an additional two weeks; no intrapartum infections were observed and the rate of serious adverse events among infants receiving intensified prophylaxis was lower than in a historical observational cohort (128).<\/li>&#13;\n\t<li>None of the studies reviewed addressed infants identified in the postpartum period or infants exposed to an incident HIV infection either during pregnancy or while breastfeeding. However, the findings of the systematic review could probably be applied to these settings as well.<\/li>&#13;\n<\/ul><p>The recommendations for extended prophylaxis for breastfeeding infants are predicated on maternal ART being initiated at or before the time when infant prophylaxis is begun (whether at birth or when maternal HIV is first detected postpartum), since infant prophylaxis is intended only to provide a bridge of protection to the infant during the period that maternal viral load is decreasing on ART.<\/p>&#13;\n&#13;\n<h5>Defining high-risk infants<\/h5>&#13;\n&#13;\n<p>The 2016 WHO consolidated HIV guidelines acknowledge a range of factors to be considered when assessing risk, including examples from countries that stratify HIV-exposed infants according to risk <em>(13).<\/em> Factors such as prolonged rupture of membranes, preterm delivery and low birth weight are no longer associated with increased risk of transmission when mothers are receiving ART. The critical determinants of transmission risk in the ART era are maternal viral load and duration of maternal ART.<\/p>&#13;\n&#13;\n<p>Whenever possible, use same-day point-of-care testing for viral load testing of pregnant and breastfeeding women to expedite the return of results and clinical decision-making (see subsection 4.72). If this is not available, viral load specimens and results for pregnant and breastfeeding women should be given priority across the laboratory referral process (including specimen collection, testing and return of results). The 2021 WHO clinical guidelines <em>(12)<\/em> also state that for all pregnant women, regardless of ART initiation timing, viral load testing should be performed at 34-36 weeks of gestation (or at the latest at delivery) to identify women who may be at risk of treatment failure and\/or may deliver infants at higher risk of perinatal transmission.<\/p>&#13;\n&#13;\n<p>In this context, the following scenarios may be considered as working definitions of high risk:<\/p>&#13;\n&#13;\n<ul><li>born to women with established HIV infection who have received less than four weeks of ART at the time of delivery; or<\/li>&#13;\n\t<li>born to women with established HIV infection with viral load &gt;1000 copies\/mL in the four weeks before delivery, if viral load is available; or<\/li>&#13;\n\t<li>born to women with incident HIV infection during pregnancy or breastfeeding; or<\/li>&#13;\n\t<li>born to women identified for the first time during the postpartum period, with or without a negative HIV test prenatally.<\/li>&#13;\n<\/ul><h5><img alt=\" Algorithm for risk assessment at the time of delivery to help identify infants at high and low risk of infection\" data-entity-type=\"file\" data-entity-uuid=\"4b4b93b6-cb8e-4931-814d-756912186bc3\" src=\"data:image\/gif;base64,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\" \/><\/h5>&#13;\n&#13;\n<h5>Implementation considerations<\/h5>&#13;\n&#13;\n<p>Providing multiple drugs to newborns is challenging from an operational perspective, and although AZT and NVP are proposed based on the available data, one is administered once daily and the other twice daily. Provider training will be critical to the successful uptake of these recommendations, and innovative approaches to dosing (such as using twice-daily dosing of NVP) may help to simplify administration. When the recommended regimen is not available or feasible, use of alternative options such as RAL, 3TC, LPV\/r solid formulations or triple-drug fixed-dose combinations containing AZT, NVP and 3TC may be considered (the dosing recommendations can be found in Annex 1).<\/p>&#13;\n&#13;\n<p>Consistent with the recommendations on early infant diagnosis, no specific approach to the testing of high-risk newborns is recommended. However, birth infant diagnostic NAT testing may be considered. In addition, infants who are first identified as HIV exposed postpartum have a high cumulative risk of already having acquired HIV by the time prophylaxis is initiated, and an HIV NAT test should be performed around the time of initiating prophylaxis. This will help to minimize the risk that extended prophylaxis among infected infants will lead to the development of resistance and will help promote linkage to timely initiation of ART.<\/p>&#13;\n&#13;\n<p>Some programmes have adopted enhanced prophylaxis for all HIV-exposed infants. Although this may simplify decision-making, it increases costs and exposes many infants who may not need enhanced prophylaxis to added toxicity. This type of approach ought to be reserved for selected situations in which a majority of mothers are at high risk of transmitting HIV. Data on the average duration of ART at delivery and, where available, the proportion of pregnant women with viral load &gt;1000 copies\/mL at the end of the third trimester might help policy\u00admakers to determine whether the potential benefit outweighs the added costs and toxicity. Even then, it should only be an interim measure while strategies to increase the coverage of maternal testing, early treatment and improved adherence are being implemented.<\/p>&#13;\n&#13;\n<p>However, there are several situations where suppression of viral loads throughout the breastfeeding period cannot be ensured in the mother, for example:<\/p>&#13;\n&#13;\n<ul><li>if a mother refuses or is unable to start or continue ART and intends to breastfeed her infant;<\/li>&#13;\n\t<li>if the provider knows the mother is poorly adherent to ART while breastfeeding; and<\/li>&#13;\n\t<li>if maternal viral load is known to be elevated when the infant prophylaxis regimen is about to be stopped.<\/li>&#13;\n<\/ul><p>There is no formal recommendation for these types of situations and no evidence to guide the best course of action. It is reasonable, however, to assume that infant prophylaxis serves as a back-up solution for preventing postnatal transmission of HIV, and national programmes could consider the merits of giving clinical providers the option of continuing infant prophylaxis beyond the recommended 6- or 12-week period. If this option is provided in the national guidelines, there ought to be clearly defined scenarios in which continuing prophylaxis is warranted. National guidelines should also emphasize that the best way to prevent breast-milk transmission of HIV is by optimal maternal treatment for the entire duration of exposure. Continuing prophylaxis should therefore be seen as an interim measure while efforts are made to support and improve maternal treatment adherence. Deciding to continue prophylaxis should consider the factors that led to poor maternal adherence since they may affect adherence to infant prophylaxis. Once stopped, infant prophylaxis should not be restarted if there are fresh concerns about maternal adherence. No evidence supports such an approach; instead the focus should be on determining why the mother was unable to remain adherent. If the decision has been made to continue infant prophylaxis, mothers and infants should be evaluated at regular intervals to assess the need for ongoing infant prophylaxis.<\/p>&#13;\n&#13;\n<h5>Research gaps<\/h5>&#13;\n&#13;\n<p>Potential areas for research include clinical and pharmacological studies to inform the development of improved ARV drug formulations, including fixed-dose combinations in appropriate doses for newborns and infants. Research into the use of alternative drugs for prophylaxis that are better tolerated and that may have greater efficacy for infant prophylaxis such as integrase inhibitors could also be considered. Studies to evaluate the clinical relevance of postnatal viraemic episodes in breastfeeding mothers and the relative contribution of such episodes to infant HIV infection are needed, coupled with evaluation of whether enhanced prophylaxis adds additional benefit in a population with a well-implemented effective maternal ART programme but known difficulty with adherence and viraemia in the postpartum period.<\/p>&#13;\n&#13;\n<p>Finally, implementation science research to evaluate the optimal definition of high risk in the context of universal maternal ART and the impact of various service delivery models and how they affect adherence to enhanced postnatal prophylaxis and retention would be of great value.<\/p>&#13;\n&#13;\n<div class=\"new_recommend \">&#13;\n<h5><strong>Box 3.2<\/strong> Improving service delivery and implementing a postnatal package of care<\/h5>&#13;\n&#13;\n<p>There are several barriers to the uptake of effective infant HIV services, and no single intervention can address all the barriers facing women and their infants at different times and places. Socioeconomic and traditional factors that keep mother-infant pairs together are among the enabling circumstances that improve service uptake. Programmes could benefit from combining effective interventions into service packages to support service provision and focus on the community engagement that supports uptake.<\/p>&#13;\n&#13;\n<p>Interventions that have been proven to improve the provision and uptake of infant HIV services and the retention of mother-infant pairs include:<\/p>&#13;\n&#13;\n<ul><li>client-focused interventions that provide support to individual clients using reminder text messaging, conditional cash incentives and male partner involvement; and<\/li>&#13;\n\t<li>health system-focused interventions, including measures to enhance the programme (point-of-care testing technologies, provider training and support, enhanced counselling services and peer support), to strengthen the health system (initiatives to improve quality and integrating maternal, newborn and child health and HIV services) and to support community-based services and health-care workers.<\/li>&#13;\n<\/ul><p>Promoting integration to reduce fragmentation of care for mothers and infants and ensure that infants remain in the testing cascade until final diagnosis should be a priority. Strong antenatal and well-baby care systems provide opportunities to strengthen service delivery for HIV-exposed infants. Integration within a well-established maternal, neonatal and child services platform, which traditionally provides services closest to clients, facilitates mother-infant pair follow-up and reduces the cost and time-visit burden on clients (integrated information systems that link mother and infant information improve client tracking and facilitate the continuity of care provision). Examples include longitudinal follow-up registers and cohort analysis and linkage with information on community services. Programmes should, however, consider the increasing burden on the maternal, newborn and child platform within the context of existing human resources and the challenges of changing services with new packages.<\/p>&#13;\n&#13;\n<p>Community engagement and community-based services play an important role in supporting HIV-exposed infant care. These clear and highly context-specific services play a boosting role in supporting facility-focused services and include community-based HIV testing. The engagement of networks of women living with HIV has been effective in several countries and has been used to improve community HIV literacy to create demand, form support groups at the facility and community levels, strengthen linkage to care by escorting newly diagnosed clients to treatment clinics, conducting defaulter tracking and providing active follow-up of mother-infant pairs. In several settings, these interventions led to reduced loss to follow-up among mother-infant pairs.<\/p>&#13;\n&#13;\n<p>Ensuring provision of a comprehensive integrated postnatal package of HIV services will promote delivery of a set of interventions that contributes not only to improved HIV outcomes but better early childhood development overall.<\/p>&#13;\n<\/div>&#13;\n&#13;\n<ol><li>Smith DK, Herbst JH, Zhang X, Rose CE. Condom effectiveness for HIV prevention by consistency of use among men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2015;68:337-44.<\/li>&#13;\n\t<li>Weller SC, Davis-Beaty K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev. 2002;(1):CD003255.<\/li>&#13;\n\t<li>French P, Latka M, Gollub E, Rogers C, Hoover D, Stein Z. Use-effectiveness of the female versus male condom in preventing sexually transmitted disease in women. Sex Transm Dis. 2003;30:433-9.<\/li>&#13;\n\t<li>Effectiveness of sterile needle and syringe programming in reducing HIV\/AIDS among injecting drug users. Geneva: World Health Organization; 2004 (<a href=\"https:\/\/apps.who.int\/iris\/handle\/10665\/43107\">https:\/\/apps.who.int\/iris\/ handle\/10665\/43107<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>Effectiveness of drug dependence treatment in preventing HIV among injecting drug users. Geneva: World Health Organization; 2005 (<a href=\"https:\/\/apps.who.int\/iris\/handle\/10665\/43259\">https:\/\/apps.who.int\/iris\/ handle\/10665\/43259<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Geneva: World Health Organization; 2009 (<a href=\"https:\/\/apps.who.int\/iris\/handle\/10665\/43948\">https:\/\/apps.who.int\/iris\/ handle\/10665\/43948<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>Community management of opioid overdose. Geneva: World Health Organization; 2014 (<a href=\"https:\/\/apps.who.int\/iris\/handle\/10665\/137462\">https:\/\/apps.who.int\/iris\/ handle\/10665\/137462<\/a>\u00a0accessed 1 June 2021).<\/li>&#13;\n\t<li>Preventing HIV through safe voluntary medical male circumcision for adolescent boys and men in generalized HIV epidemics: recommendations and key considerations. Geneva: World Health Organization; 2020 (<a href=\"https:\/\/apps.who.int\/iris\/handle\/10665\/333850\">https:\/\/apps.who.int\/iris\/handle\/10665\/333850<\/a> accessed 1 June 2021)<\/li>&#13;\n\t<li>Farley TM, Samuelson J, Grabowski MK, Ameyan W, Gray RH, Baggaley R. Impact of male circumcision on risk of HIV infection in men in a changing epidemic context-systematic review and meta-analysis. J Int AIDS Soc. 2020;23:e25490.<\/li>&#13;\n\t<li>Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. Geneva: World Health Organization; 2014 (<a href=\"https:\/\/apps.who.int\/iris\/handle\/10665\/128048\">https:\/\/apps.who.int\/iris\/ handle\/10665\/128048<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. Geneva: World Health Organization; 2016 (<a href=\"https:\/\/apps.who.int\/iris\/handle\/10665\/246200\">https:\/\/apps.who.int\/iris\/ handle\/10665\/246200<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>Guidelines: updated recommendations on HIV prevention, infant diagnosis, antiretroviral initiation and monitoring. Geneva: World Health Organization; 2021 (<a href=\"https:\/\/apps.who.int\/iris\/handle\/10665\/340190\">https:\/\/apps.who.int\/ iris\/handle\/10665\/340190<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach - second edition. Geneva: World Health Organization; 2016 (<a href=\"https:\/\/apps.who.int\/iris\/handle\/10665\/208825\">https:\/\/apps.who.int\/iris\/handle\/10665\/208825<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>Guidance on oral pre-exposure prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV: recommendations for use in the context of demonstration projects. Geneva: World Health Organization; 2012 (<a href=\"https:\/\/apps.who.int\/iris\/handle\/10665\/75188\">https:\/\/apps.who.int\/iris\/handle\/10665\/75188<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>Fonner VA, Dalglish SL, Kennedy CE, Baggaley R, O'Reilly KR, Koechlin FM et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS. 2016;30:1973-83.<\/li>&#13;\n\t<li>WHO implementation tool for pre-exposure prophylaxis of HIV infection. Geneva: World Health Organization; 2017 (<a href=\"https:\/\/apps.who.int\/iris\/handle\/10665\/255890\">https:\/\/apps.who.int\/iris\/handle\/10665\/255890<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>WHO technical brief: preventing HIV during pregnancy and breastfeeding in the context of PrEP. Geneva: World Health Organization; 2017 (<a href=\"https:\/\/apps.who.int\/iris\/handle\/10665\/255866\">https:\/\/apps.who.int\/iris\/ handle\/10665\/255866<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>Update on antiretroviral regimens for treating and preventing HIV infection and update on early infant diagnosis of HIV: interim guidance. Geneva: World Health Organization; 2018 (<a href=\"https:\/\/apps.who.int\/iris\/handle\/10665\/273129\">https:\/\/apps.who.int\/iris\/handle\/10665\/273129<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>What's the 2+1+1? Event driven PrEP to prevent HIV in gay men and other men who have sex with men: update to WHO's recommendation on oral PrEP. Geneva: World Health Organization 2019 (<a href=\"https:\/\/apps.who.int\/iris\/handle\/10665\/325955\">https:\/\/apps.who.int\/iris\/handle\/10665\/325955<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>Technical brief: prevention and control of sexually transmitted infections (STIs) in the era of pre-exposure prophylaxis (PrEP) for HIV. Geneva: World Health Organization; 2019 (<a href=\"https:\/\/apps.who.int\/iris\/handle\/10665\/325908\">https:\/\/apps.who.int\/iris\/handle\/10665\/325908<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>Schaefer R, Schmidt H-M, Ravasi G, Mozalevskis A, Rewari BB, Lule F et al. Global adoption of guidelines on and use of oral pre-exposure prophylaxis (PrEP): current situation and future projects. Lancet HIV. In press.<\/li>&#13;\n\t<li>Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva: World Health Organization; 2015 (<a href=\"https:\/\/apps.who.int\/iris\/handle\/10665\/186275\">https:\/\/apps.who.int\/iris\/handle\/10665\/186275<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>Chou R, Evans C, Hoverman A, Sun C, Dana T, Bougatsos C et al. Preexposure prophylaxis for the prevention of HIV infection: evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2019;321:2214-30.<\/li>&#13;\n\t<li>Baeten JM, Donnell D, Mugo NR, Ndase P, Thomas KK, Campbell JD et al. Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial. Lancet Infect Dis. 2014;14:1055-64.<\/li>&#13;\n\t<li>Wilton J, Senn H, Sharma M, Tan DH. Pre-exposure prophylaxis for sexually-acquired HIV risk management: a review. HIV AIDS (Auckl). 2015;7:125.<\/li>&#13;\n\t<li>Deutsch MB, Glidden DV, Sevelius J, Keatley J, McMahan V, Guanira J et al. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial. Lancet HIV. 2015;2:e512-9.<\/li>&#13;\n\t<li>Pacifico de Carvalho N, Mendicino CCP, Candido RCF, Alecrim DJD, Menezes de Padua CA. HIV pre-exposure prophylaxis (PrEP) awareness and acceptability among trans women: a review. AIDS Care. 2019;31:1234-40.<\/li>&#13;\n\t<li>Martin M, Vanichseni S, Suntharasamai P, Sangkum U, Mock PA, Gvetadze RJ et al. Renal function of participants in the Bangkok tenofovir study - Thailand, 2005-2012. Clin Infect Dis. 2014;59:716-24.<\/li>&#13;\n\t<li>Solomon MM, Lama JR, Glidden DV, Mulligan K, McMahan V, Liu AY et al. Changes in renal function associated with oral emtricitabine\/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis. AIDS. 2014;28:851.<\/li>&#13;\n\t<li>Liu AY, Vittinghoff E, Sellmeyer DE, Irvin R, Mulligan K, Mayer K et al. Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco. PLoS One. 2011;6:e23688.<\/li>&#13;\n\t<li>Van De Vijver DA, Nichols BE, Abbas UL, Boucher CA, Cambiano V, Eaton JW et al. Preexposure prophylaxis will have a limited impact on HIV-1 drug resistance in sub-Saharan Africa: a comparison of mathematical models. AIDS. 2013;27:2943-51.<\/li>&#13;\n\t<li>Gibas KM, van den Berg P, Powell VE, Krakower DS. Drug resistance during HIV pre\u00adexposure prophylaxis. Drugs. 2019;79:609-19.<\/li>&#13;\n\t<li>Marcus JL, Glidden DV, Mayer KH, Liu AY, Buchbinder SP, Amico KR et al. No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis. PLoS One. 2013;8:e81997.<\/li>&#13;\n\t<li>Guest G, Shattuck D, Johnson L, Akumatey B, Clarke EEK, Chen P-L et al. Changes in sexual risk behavior among participants in a PrEP HIV prevention trial. Sex Transm Dis. 2008;35:1002-8.<\/li>&#13;\n\t<li>Holt M, Broady TR, Mao L, Chan C, Rule J, Ellard J et al. Increasing preexposure prophylaxis use and 'net prevention coverage' in behavioural surveillance of Australian gay and bisexual men. AIDS. 2021;35:835-40.<\/li>&#13;\n\t<li>Quaife M, MacGregor L, Ong JJ, Gafos M, Torres-Rueda S, Grant H et al. Risk compensation and sexually transmitted infection incidence in PrEP programmes. Lancet HIV. 2020;7:e222-3.<\/li>&#13;\n\t<li>Rojas Castro D, Delabre RM, Molina JM. Give PrEP a chance: moving on from the \"risk compensation\" concept. J Int AIDS Soc. 2019;22(Suppl. 6):e25351.<\/li>&#13;\n\t<li>Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399-410.<\/li>&#13;\n\t<li>Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367:411-22.<\/li>&#13;\n\t<li>Yager JL, Anderson PL. Pharmacology and drug interactions with HIV PrEP in transgender persons receiving gender affirming hormone therapy. Expert Opin Drug Metab Toxicol. 2020;16:463-74.<\/li>&#13;\n\t<li>Hiransuthikul A, Janamnuaysook R, Himmad K, Kerr SJ, Thammajaruk N, Pankam T et al. Drug-drug interactions between feminizing hormone therapy and pre-exposure prophylaxis among transgender women: the iFACT study. J Int AIDS Soc. 2019;22:e25338.<\/li>&#13;\n\t<li>Shieh E, Marzinke MA, Fuchs EJ, Hamlin A, Bakshi R, Aung W et al. Transgender women on oral HIV pre-exposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender men. J Int AIDS Soc. 2019;22:e25405.<\/li>&#13;\n\t<li>Grant RM, Pellegrini M, Defechereux PA, Anderson PL, Yu M, Glidden DV et al. Sex hormone therapy and tenofovir diphosphate concentration in dried blood spots: primary results of the iBrEATHe Study. Clin Infect Dis. 2020;ciaa1160.<\/li>&#13;\n\t<li>Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14:820-9.<\/li>&#13;\n\t<li>Hoagland B, Moreira RI, De Boni RB, Kallas EG, Madruga JV, Vasconcelos R et al. High pre-exposure prophylaxis uptake and early adherence among men who have sex with men and transgender women at risk for HIV Infection: the PrEP Brasil demonstration project. J Int AIDS Soc. 2017;20:21472.<\/li>&#13;\n\t<li>Untangling the web of antiretroviral price reductions. Geneva: Medecins Sans Frontieres; 2014 (<a href=\"https:\/\/msfaccess.org\/sites\/default\/files\/MSF_UTW_17th_Edition_4_b.pdf\">https:\/\/www.msfaccess.org\/sites\/default\/files\/MSF_UTW_17th_Edition_4_b.pdf<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>Koechlin FM, Fonner VA, Dalglish SL, O'Reilly KR, Baggaley R, Grant RM et al. Values and preferences on the use of oral pre-exposure prophylaxis (PrEP) for HIV prevention among multiple populations: a systematic review of the literature. AIDS Behav. 2017;21:1325-35.<\/li>&#13;\n\t<li>Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372:509-18.<\/li>&#13;\n\t<li>Bekker L-G, Hughes J, Amico R, Roux S, Hendrix C, Anderson PL et al. HPTN 067\/ADAPT Cape Town: a comparison of daily and nondaily PrEP dosing in African women. 22nd Conference on Retroviruses and Opportunistic Infections, Seattle, WA, USA, 23-26 February 2015 (<a href=\"https:\/\/www.croiconference.org\/abstract\/hptn-067adapt-cape-town-comparison-daily-and-nondaily-prep-d\">https:\/\/www.croiconference.org\/abstract\/hptn-067adapt-cape-town-comparison-daily-and-nondaily-prep-dosing-african-women<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>Henderson F, Taylor A, Chirwa L, Williams T, Borkowf C, Kasonde M et al. Characteristics and oral PrEP adherence in the TDF2 open-label extension in Botswana. J Int AIDS Soc. 2015;18.<\/li>&#13;\n\t<li>Baeten J, Heffron R, Kidoguchi L, Mugo N, Katabira E, Bukusi E. Partners Demonstration Project Team. Near elimination of HIV transmission in a demonstration project of PrEP and ART. 22nd Conference on Retroviruses and Opportunistic Infections, Seattle, WA, USA, 23-26 February 2015 (<a href=\"https:\/\/www.croiconference.org\/abstract\/near-elimination-hiv-transmission-demonstration-project-prep\">https:\/\/www.croiconference.org\/abstract\/near-elimination-hiv-transmission-demonstration-project-prep-and-art<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>McCormack S, Dunn D. Pragmatic open-label randomised trial of preexposure prophylaxis: the PROUD study. 22nd Conference on Retroviruses and Opportunistic Infections, Seattle, WA, USA, 23-26 February 2015 (<a href=\"https:\/\/www.croiconference.org\/abstract\/pragmatic-open-label-randomised-trial-preexposure-prophylaxi\">https:\/\/www.croiconference.org\/abstract\/pragmatic-open-label-randomised-trial-preexposure-prophylaxis-proud-study<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>Grant RM, Mannheimer S, Hughes JP, Hirsch-Moverman Y, Loquere A, Chitwarakorn A. Daily and nondaily oral preexposure prophylaxis in men and transgender women who have sex with men: the Human Immunodeficiency Virus Prevention Trials Network 067\/ ADAPT Study. Clin Infect Dis. 2018;66:1712-21.<\/li>&#13;\n\t<li>Holtz T, Chitwarakorn A, Curlin M, Hughes J, Amico K, Hendrix C et al. HPTN 067\/ADAPT study: a comparison of daily and non-daily pre-exposure prophylaxis dosing in Thai men who have sex with men, Bangkok, Thailand. J Int AIDS Soc. 2015;18.<\/li>&#13;\n\t<li>Liu A, Cohen S, Vittinghoff E, Anderson P, Doblecki-Lewis S, Bacon O. Adherence, sexual behavior and HIV\/STI incidence among men who have sex with men (MSM) and transgender women (TGW) in the US PrEP demonstration (Demo) project. 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Vancouver, Canada, 18-22 July 2015 (<a href=\"https:\/\/www.natap.org\/2015\/IAS\/IAS_80.htm\">https:\/\/www.natap.org\/2015\/IAS\/IAS_80.htm<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>Hosek S, Rudy B, Landovitz R, Kapogiannis B, Siberry G, Rutledge B et al. An HIV pre-exposure prophylaxis (PrEP) demonstration project and safety study for young gay men and other men who have sex with men. J Acquir Immune Defic Syndr. 2017;74:21.<\/li>&#13;\n\t<li>Machtinger EL, Cuca YP, Khanna N, Rose CD, Kimberg LS. From treatment to healing: the promise of trauma-informed primary care. Womens Health Issues. 2015;25:193-7.<\/li>&#13;\n\t<li>Bekker L-G, Johnson L, Cowan F, Overs C, Besada D, Hillier S et al. Combination HIV prevention for female sex workers: what is the evidence? Lancet. 2015;385:72-87.<\/li>&#13;\n\t<li>Schaefer R, Amparo da Costa Leite P, Silva R, Abdool Karim Q, Akolo C, Caceres C et al. Kidney function in oral pre-exposure prophylaxis users: a systematic literature review and individual patient data meta-analysis. In preparation.<\/li>&#13;\n\t<li>Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Geneva: World Health Organization; 2015 (<a href=\"https:\/\/apps.who.int\/iris\/handle\/10665\/154590\">https:\/\/apps.who.int\/iris\/ handle\/10665\/154590<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>World Health Organization. Hepatitis B vaccines: WHO position paper - July 2017. Wkly Epidemiol Rec. 2017;92:369-92 (<a href=\"https:\/\/apps.who.int\/iris\/handle\/10665\/255873\">https:\/\/apps.who.int\/iris\/handle\/10665\/255873<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587-99.<\/li>&#13;\n\t<li>Peterson L, Taylor D, Roddy R, Belai G, Phillips P, Nanda K et al. Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. PLOS Clin Trial. 2007;2:e27.<\/li>&#13;\n\t<li>Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. Geneva: World Health Organization; 2018 (<a href=\"http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/273174\/9789241550345-eng.pdf\">http:\/\/apps.who.int\/iris\/bitstream\/ha ndle\/10665\/273174\/9789241550345-eng.pdf<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>Holtz T, Chitwarakorn A, Curlin M, Hughes J, Amico K, Hendrix C. HPTN 067\/ADAPT study: a comparison of daily and non-daily pre-exposure prophylaxis dosing in Thai men who have sex with men, Bangkok, Thailand. J Int AIDS Soc. 2015;18.<\/li>&#13;\n\t<li>Cottrell ML, Yang KH, Prince HM, Sykes C, White N, Malone S et al. A translational pharmacology approach to predicting outcomes of preexposure prophylaxis against HIV in men and women using tenofovir disoproxil fumarate with or without emtricitabine. J Infect Dis. 2016;214:55-64.<\/li>&#13;\n\t<li>Guidelines on post-exposure prophylaxis for HIV and the use of co-trimoxazole prophylaxis for HIV-related infections among adults, adolescents and children: recommendations for a public health approach. Geneva: World Health Organization; 2014 (<a href=\"https:\/\/apps.who.int\/iris\/handle\/10665\/145719\">https:\/\/apps.who.int\/iris\/handle\/10665\/145719<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>Joseph Davey DL, Pintye J, Baeten JM, Aldrovandi G, Baggaley R, Bekker LG et al. Emerging evidence from a systematic review of safety of pre-exposure prophylaxis for pregnant and postpartum women: where are we now and where are we heading? J Int AIDS Soc. 2020;23:e25426.<\/li>&#13;\n\t<li>Mistler CB, Copenhaver MM, Shrestha R. The pre-exposure prophylaxis (PrEP) care cascade in people who inject drugs: a systematic review. AIDS Behav. 2021;25:1490-506.<\/li>&#13;\n\t<li>Dapivirine vaginal ring 25 mg (dapivirine): an overview of dapivirine vaginal ring 25 mg and why it received a positive opinion. Amsterdam: European Medicines Agency; 2020 (<a href=\"https:\/\/www.ema.europa.eu\/en\/documents\/medicine-outside-eu\/dapivirine-vaginal-ring-25-mg-medicine-overview_en.pdf\">https:\/\/www.ema.europa.eu\/en\/documents\/medicine-outside-eu\/dapivirine-vaginal-ring-25-mg-medicine-overview_en.pdf<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>Assessment report: dapivirine vaginal ring 25 mg. Amsterdam: European Medicines Agency; 2020 (<a href=\"https:\/\/www.ema.europa.eu\/en\/documents\/medicine-outside-eu\/dapivirine-vaginal-ring-25-mg-public-assessment-report_en.pdf\">https:\/\/www.ema.europa.eu\/en\/documents\/medicine-outside-eu\/ dapivirine-vaginal-ring-25-mg-public-assessment-report_en.pdf<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>Ahmed K, Baeten JM, Beksinska M, Bekker L-G, Bukusi EA, Donnell D et al. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial. Lancet. 2019;394:303-13.<\/li>&#13;\n\t<li>Celum C, Delany-Moretlwe S, Hosek S, Dye B, Bekker L-G, Mgodi N. Risk behavior, perception, and reasons for PrEP among young African women in HPTN 082. 23rd Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA, 22-25 February 2016 (<a href=\"https:\/\/www.croiconference.org\/abstract\/risk-behavior-perception-and-reasons-prep-among-young-africa\">https:\/\/www.croiconference.org\/abstract\/risk-behavior-perception-and-reasons-prep-among-young-african-women-hptn-082<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>Koss C, Havlir D, Ayieko J, Kwarisiima D, Kabami J, Atukunda M. Lower than expected HIV incidence among men and women at elevated HIV risk in a population-based PrEP study in rural Kenya and Uganda: interim results from the SEARCH study. 23rd International AIDS Conference, virtual, 6-10 July 2020 (<a href=\"https:\/\/aids2020.org\/wp-content\/uploads\/2020\/07\/HIV-Highlights-Press-Conference-Abstracts.pdf\">https:\/\/aids2020.org\/wp-content\/ uploads\/2020\/07\/HIV-Highlights-Press-Conference-Abstracts.pdf<\/a>, accessed 1 June 2021)<\/li>&#13;\n\t<li>Velloza J, Khoza N, Scorgie F, Chitukuta M, Mutero P, Mutiti K et al. The influence of HIV-related stigma on PrEP disclosure and adherence among adolescent girls and young women in HPTN 082: a qualitative study. J Int AIDS Soc. 2020;23:e25463.<\/li>&#13;\n\t<li>Scorgie F, Khoza N, Baron D, Lees S, Harvey S, Ramskin L et al. Disclosure of PrEP use by young women in South Africa and Tanzania: qualitative findings from a demonstration project. Cult Health Sex. 2021;23:257-72.<\/li>&#13;\n\t<li>Corneli A, Perry B, McKenna K, Agot K, Ahmed K, Taylor J et al. Participants' explanations for nonadherence in the FEM-PrEP clinical trial. J Acquir Immune Defic Syndr. 2016;71:452-61.<\/li>&#13;\n\t<li>7Montgomery ET, Beksinska M, Mgodi N, Schwartz J, Weinrib R, Browne EN et al. End-user preference for and choice of four vaginally delivered HIV prevention methods among young women in South Africa and Zimbabwe: the Quatro Clinical Crossover Study. J Int AIDS Soc. 2019;22:e25283.<\/li>&#13;\n\t<li>van der Straten A, Agot K, Ahmed K, Weinrib R, Browne EN, Manenzhe K et al. The Tablets, Ring, Injections as Options (TRIO) study: what young African women chose and used for future HIV and pregnancy prevention. J Int AIDS Soc. 2018;21:e25094.<\/li>&#13;\n\t<li>Nel A, Bekker L-G, Bukusi E, HellstrElm E, Kotze P, Louw C et al. Safety, acceptability and adherence of dapivirine vaginal ring in a microbicide clinical trial conducted in multiple countries in sub-Saharan Africa. PLoS One. 2016;11:e0147743.<\/li>&#13;\n\t<li>Baeten JM, Palanee-Phillips T, Brown ER, Schwartz K, Soto-Torres LE, Govender V et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med. 2016;375:2121-32.<\/li>&#13;\n\t<li>Brown ER, Hendrix CW, van der Straten A, Kiweewa FM, Mgodi NM, Palanee-Philips T et al. Greater dapivirine release from the dapivirine vaginal ring is correlated with lower risk of HIV-1 acquisition: a secondary analysis from a randomized, placebo-controlled trial. J Int AIDS Soc. 2020;23:e25634.<\/li>&#13;\n\t<li>Nel A, van Niekerk N, Van Baelen B, Malherbe M, Mans W, Carter A et al. Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension study. Lancet HIV. 2021;8:e77-86.<\/li>&#13;\n\t<li>Baeten JM, Palanee-Phillips T, Mgodi NM, Mayo AJ, Szydlo DW, Ramjee G et al. Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study. Lancet HIV. 2021;8:e87-95.<\/li>&#13;\n\t<li>Brown ER, Hendrix CW, van der Straten A, Kiweewa FM, Mgodi NM, Palanee-Philips T et al. Greater dapivirine release from the dapivirine vaginal ring is correlated with lower risk of HIV-1 acquisition: a secondary analysis from a randomized, placebo-controlled trial. J Int AIDS Soc. 2020;23:e25634.<\/li>&#13;\n\t<li>MTN-042 - A study of PrEP and the dapivirine ring in pregnant women. Microbicide Trials Network; 2020 (<a href=\"https:\/\/mtnstopshiv.org\/research\/studies\/mtn-042\">https:\/\/mtnstopshiv.org\/research\/studies\/mtn-042<\/a>).<\/li>&#13;\n\t<li>MTN-043 - B-PROTECTED: Breastfeeding. PrEP &amp; ring open-label trial. Microbicide Trials Network; 2020 (<a href=\"https:\/\/mtnstopshiv.org\/news\/studies\/mtn043\">https:\/\/mtnstopshiv.org\/news\/studies\/mtn043<\/a>).<\/li>&#13;\n\t<li>Rosenberg Z, Nel A, van Niekerk N, Van Baelen B, Van Roey J, Palanee-Phillips T et al. Pooled efficacy analysis of two Phase III trials of dapivirine vaginal ring for the reduction of HIV-1 infection risk in HIV-uninfected women in sub-Saharan Africa. 9th IAS Conference on HIV Science, Paris, France, 23-26 July 2017 (<a href=\"https:\/\/www.ipmglobal.org\/sites\/default\/files\/ias_dpv_ring_pooled_analysis_poster_21_july_2017.pdf\">https:\/\/www.ipmglobal.org\/sites\/default\/ files\/ias_dpv_ring_pooled_analysis_poster_21_july_2017.pdf<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>Nel A, Van Baelen BE, Mans W, Louw C, Gama C, Mabude Z et al. Dapivirine vaginal ring reduces the risk of HIV-1 infection among women in Africa. 9th South Africa AIDS Conference, Durban, South Africa, 11-14 June 2019.<\/li>&#13;\n\t<li>Nel A, van Niekerk N, Kapiga S, Bekker L-G, Gama C, Gill K et al. Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. N Engl J Med. 2016;375:2133-43.<\/li>&#13;\n\t<li>Fonner V, Dalglish S. Dapivirine intervaginal ring as pre-exposure prophylaxis to prevent HIV among women at substantial risk of infection: a systematic review and meta-analysis. Unpublished.<\/li>&#13;\n\t<li>Palanee-Phillips T, Roberts ST, Reddy K, Govender V, Naidoo L, Siva S et al. Impact of partner-related social harms on women's adherence to the dapivirine vaginal ring during a phase III trial. J Acquir Immune Defic Syndr. 2018;79:580.<\/li>&#13;\n\t<li>Balkus JE, Palanee-Phillips T, Reddy K, Siva S, Harkoo I, Nakabiito C et al. Dapivirine vaginal ring use does not diminish the effectiveness of hormonal contraception. J Acquir Immune Defic Syndr. 2017;76:e47.<\/li>&#13;\n\t<li>Makanani B, Balkus JE, Jiao Y, Noguchi LM, Palanee-Phillips T, Mbilizi Y et al. Pregnancy and infant outcomes among women using the dapivirine vaginal ring in early pregnancy. J Acquir Immune Defic Syndr. 2018;79:566.<\/li>&#13;\n\t<li>Kusemererwa S, Abaasa A. Pregnancy incidence and outcomes among women using dapivirine vaginal ring for HIV prevention in a phase III clinical trial in south western Uganda. HIV Research for Prevention Meeting, Madrid, Spain, 21-25 October 2018 (<a href=\"https:\/\/www.liebertpub.com\/doi\/10.1089\/aid.2018.5000.abstracts\">https:\/\/www.liebertpub.com\/doi\/10.1089\/aid.2018.5000.abstracts<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>Kusemererwa S, Abaasa A. Does the use of the dapivirine vaginal ring result in change in risk sexual behavior? HIV Research for Prevention Meeting, Madrid, Spain, 21-25 October 2018 (<a href=\"https:\/\/www.liebertpub.com\/doi\/10.1089\/aid.2018.5000.abstracts\">https:\/\/www.liebertpub.com\/doi\/10.1089\/aid.2018.5000.abstracts<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>Glaubius R, Ding Y, Penrose KJ, Hood G, Engquist E, Mellors JW et al. Dapivirine vaginal ring for HIV prevention: modelling health outcomes, drug resistance and cost-effectiveness. J Int AIDS Soc. 2019;22:e25282.<\/li>&#13;\n\t<li>Glaubius R, Penrose KJ, Hood G, Parikh UM, Abbas U. Dapivirine vaginal ring preexposure prophylaxis for HIV prevention in South Africa. Topics Antivir Med. 2016;24(E-1):458.<\/li>&#13;\n\t<li>Smith J, Harris K, Garnett G, Van Damme L, Hallett T. Cost-effectiveness of the intravaginal dapivirine ring: a modeling analysis. Topics Antivir Med. 2016;24(E-1):458.<\/li>&#13;\n\t<li>Reidy M, Gardiner E, Pretorius C, Glaubius R, Torjesen K, Kripke K. Evaluating the potential impact and cost-effectiveness of dapivirine vaginal ring pre-exposure prophylaxis for HIV prevention. PLoS One. 2019;14:e0218710.<\/li>&#13;\n\t<li>Kripke K, Reidy M, Bhavaraju N, Torjesen K, Gardiner E. Modeling the potential impact of the dapivirine ring for HIV prevention. 22nd International AIDS Society Conference, Amsterdam, Netherlands, 23-27 July 2018 (<a href=\"https:\/\/www.prepwatch.org\/wp-content\/uploads\/2018\/08\/OPTIONS_DapRingModeling_AIDS2018poster-1.pdf\">https:\/\/www.prepwatch.org\/wp-content\/ uploads\/2018\/08\/OPTIONS_DapRingModeling_AIDS2018poster-1.pdf<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>Nel A, Haazen W, Nuttall J, Romano J, Rosenberg Z, van Niekerk N. A safety and pharmacokinetic trial assessing delivery of dapivirine from a vaginal ring in healthy women. AIDS. 2014;28:1479-87.<\/li>&#13;\n\t<li>Chen BA, Zhang J, Gundacker HM, Hendrix CW, Hoesley CJ, Salata RA et al. Phase 2a safety, pharmacokinetics, and acceptability of dapivirine vaginal rings in US postmenopausal women. Clin Infect Dis. 2019;68:1144-51.<\/li>&#13;\n\t<li>Bunge KE, Levy L, Szydlo DW, Zhang J, Gaur AH, Reirden D et al. Brief report: phase IIa safety study of a vaginal ring containing dapivirine in adolescent young women. J Acquir Immune Defic Syndr. 2020;83:135-9.<\/li>&#13;\n\t<li>Griffin JB, Ridgeway K, Montgomery E, Torjesen K, Clark R, Peterson J et al. Vaginal ring acceptability and related preferences among women in low-and middle-income countries: a systematic review and narrative synthesis. PLoS One. 2019;14:e0224898.<\/li>&#13;\n\t<li>Schwartz K, Bhavaraju N, Ridgeway K, Gomez A. End-user perspectives on their ability, motivation and opportunity to use the dapivirine vaginal ring. 23rd International AIDS Conference, virtual, 6-10 July 2020 (<a href=\"https:\/\/programme.aids2020.org\/Abstract\/AbstractList?abstractGrid-sort=AbstractNumber-asc&amp;abstractGr\">https:\/\/programme.aids2020.org\/Abstract\/ AbstractList?abstractGrid-sort=AbstractNumber-asc&amp;abstractGrid-page=168<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>Ridgeway KM, Montgomery ET, Smith K, Torjesen K, van der Straten A, Achilles SL. Vaginal ring acceptability: a systematic review and meta-analysis of vaginal ring experiences from around the world. In preparation.<\/li>&#13;\n\t<li>van der Straten A, Panther L, Laborde N, Hoesley CJ, Cheng H, Husnik MJ et al. Adherence and acceptability of a multidrug vaginal ring for HIV prevention in a phase I study in the United States. AIDS Behav. 2016;20:2644-53.<\/li>&#13;\n\t<li>Montgomery ET, van der Straten A, Chitukuta M, Reddy K, Woeber K, Atujuna M et al. Acceptability and use of a dapivirine vaginal ring in a phase III trial. AIDS. 2017;31:1159.<\/li>&#13;\n\t<li>Chitukuta M, Duby Z, Katz A, Nakyanzi T, Reddy K, Palanee-Phillips T et al. Negative rumours about a vaginal ring for HIV-1 prevention in sub-Saharan Africa. Culture Health Sexuality. 2019;21:1209-24.<\/li>&#13;\n\t<li>Duby Z, Katz AW, Browne EN, Mutero P, Etima J, Zimba CC et al. Hygiene, blood flow, and vaginal overload: why women removed an HIV prevention vaginal ring during menstruation in Malawi, South Africa, Uganda and Zimbabwe. AIDS Behav. 2020;24:617-28.<\/li>&#13;\n\t<li>Laborde ND, Pleasants E, Reddy K, Atujuna M, Nakyanzi T, Chitukuta M et al. Impact of the dapivirine vaginal ring on sexual experiences and intimate partnerships of women in an HIV prevention clinical trial: managing ring detection and hot sex. AIDS Behav. 2018;22:437-46.<\/li>&#13;\n\t<li>Nair G, Roberts S, Baeten J, Palanee-Philips T, Katie S, Reddy K et al. Disclosure of vaginal ring use to male partners in an HIV prevention study: impact on adherence. HIV Research for Prevention Meeting, Madrid, Spain, 21-25 October 2018 (<a href=\"https:\/\/www.liebertpub.com\/doi\/10.1089\/aid.2018.5000.abstracts\">https:\/\/www.liebertpub.com\/ doi\/10.1089\/aid.2018.5000.abstracts<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>van der Straten A, Browne EN, Shapley-Quinn MK, Brown ER, Reddy K, Scheckter R et al. First impressions matter: how initial worries influence adherence to the dapivirine vaginal ring. J Acquir Immune Defic Syndr. 2019;81:304-10.<\/li>&#13;\n\t<li>Ross J, Stover J. Use of modern contraception increases when more methods become available: analysis of evidence from 1982-2009. Global Health: Sci Pract. 2013;1:203-12.<\/li>&#13;\n\t<li>Consolidated guidelines on HIV testing services. Geneva: World Health Organization; 2019 (<a href=\"https:\/\/apps.who.int\/iris\/handle\/10665\/336323\">https:\/\/apps.who.int\/iris\/handle\/10665\/336323<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>1NCT03074786: MTN-034\/REACH (Reversing the Epidemic in Africa with Choices in HIV Prevention). 2020 (<a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03074786\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03074786<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>Ford N, Shubber Z, Calmy A, Irvine C, Rapparini C, Ajose O et al. Choice of antiretroviral drugs for postexposure prophylaxis for adults and adolescents: a systematic review. Clin Infect Dis. 2015;60:S170-6.<\/li>&#13;\n\t<li>Penazzato M, Dominguez K, Cotton M, Barlow-Mosha L, Ford N. Choice of antiretroviral drugs for postexposure prophylaxis for children: a systematic review. Clin Infect Dis. 2015;60:S177-81.<\/li>&#13;\n\t<li>Responding to children and adolescents who have been sexually abused: WHO clinical guidelines. Geneva: World Health Organization; 2017 (<a href=\"https:\/\/apps.who.int\/iris\/handle\/10665\/259270\">https:\/\/apps.who.int\/iris\/ handle\/10665\/259270<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: interim guidelines: supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Geneva: World Health Organization; 2018 (<a href=\"https:\/\/apps.who.int\/iris\/handle\/10665\/277395\">https:\/\/apps.who.int\/iris\/handle\/10665\/277395<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>Wiboonchutikul S, Thientong V, Suttha P, Kowadisaiburana B, Manosuthi W. Significant intolerability of efavirenz in HIV occupational postexposure prophylaxis. J Hosp Infect. 2016;92:372-7.<\/li>&#13;\n\t<li>Guideline - updates on HIV and infant feeding: the duration of breastfeeding, and support from health services to improve feeding practices among mothers living with HIV. Geneva: World Health Organization; 2016 (<a href=\"https:\/\/apps.who.int\/iris\/handle\/10665\/246260?mode=simple\">https:\/\/apps.who.int\/iris\/ handle\/10665\/246260?mode=simple<\/a>, accessed 1 June 2021).<\/li>&#13;\n\t<li>Beste S, Essajee S, Siberry G, Hannaford A, Dara J, Sugandhi N et al. Optimal antiretroviral prophylaxis in infants at high risk of acquiring HIV: a systematic review. Pediatr Infect Dis J. 2018;37:169-75.<\/li>&#13;\n\t<li>Nielsen-Saines K, Watts DH, Veloso VG, Bryson YJ, Joao EC, Pilotto JH et al. Three postpartum antiretroviral regimens to prevent intrapartum HIV infection. N Engl J Med. 2012;366:2368-79.<\/li>&#13;\n\t<li>Coovadia HM, Brown ER, Fowler MG, Chipato T, Moodley D, Manji K et al. Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial. Lancet. 2012;379:221-8.<\/li>&#13;\n\t<li>Chiappini E, Galli L, Giaquinto C, Ene L, Goetghebuer T, Judd A et al. Use of combination neonatal prophylaxis for the prevention of mother-to-child transmission of HIV infection in European high-risk infants. AIDS. 2013;27:991-1000.<\/li>&#13;\n\t<li>Lallemant M, Amzal B, Urien S, Sripan P, Cressey T, Ngo-Giang-Huong N et al. Antiretroviral intensification to prevent intrapartum HIV transmission in late comers. J Int AIDS Soc.2015;18(5Suppl. 4):20479.<\/li>&#13;\n<\/ol>","title":"3.4 Infant prophylaxis","nid":510,"vid":2910,"created":1631546262,"changed":1640627720,"field_content_type":{"tid":1,"name":"Content","class":"content"}}